The Impact of sacubitril/valsartan on atrial fibrillation in hypertensive patients with cardiac implantable electronic devices

The Impact of sacubitril/valsartan on atrial fibrillation in hypertensive patients with cardiac implantable electronic devices - The Impact of sacubitril/valsartan on atrial fibrillation in hypertensive patients with cardiac implantable electronic devices

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049953

Enrollment

Registered

2023-04-01

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension and Atrial Fibrillation

Interventions

200 mg of sacubitril/valsartan is orally administered once daily. The dose may be adjusted according to age and symptoms, but the maximum dose is 400 mg once a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive patients more than 6 months after cardiac implantable electronic device implantation who have had a cardiac implantable electronic device detected atrial high-rate episodes within 6 months

Exclusion criteria

Exclusion criteria: Patients with sacubitril/valsartan contraindications, patients with chronic atrial fibrillation, patients with eGFR 30 mL/min/1.73 m2 or less, patients with systolic blood pressure less than 100 mmHg

Design outcomes

Primary

Measure	Time frame
number, duration, and total duration of atrial high-rate episodes	—

Secondary

Measure	Time frame
Echocardiography measurements, NT-proBNP(N-terminal pro-brain natriuretic peptide	—

Countries

Japan

Contacts

Public ContactTakanao Mine

Hyogo Medical University Department of Cardiovascular and Renal Medicine

mine@hyo-med.ac.jp+81798456552

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026